| Document Date: 2013-02-21 03:01:50
Open Document File Size: 102,47 KBShare Result on Facebook
Company LFB Biotechnologies / Biotechnologies LFB Biotechnologies / LFB Group / Thallion Pharmaceuticals Inc. / Europe About Thallion Pharmaceuticals Inc. / / Country France / United States / / Currency EUR / / Event FDA Phase / Business Partnership / / IndustryTerm biopharmaceutical / treatment of serious and often rare diseases / important product / cancer therapy / plasma-derived medicinal products / dual antibody product / medicinal products / product manufacturing / biotechnology company developing pharmaceutical products / / MedicalCondition often rare diseases / foodborne bacterial infections / Shiga toxin-producing E. coli bacterial infections / infectious disease / STEC infections / / MedicalTreatment anti-cancer therapy / intravenous infusion / / Person Guillaume Bologna / Allan Mandelzys / / Position CEO / executive VP / / Product Shigamabs / Shigamabs® / / Technology antibodies / biotechnology / treating cancer / medicinal products / / URL www.thallion.com / /
SocialTag |
- PRESS RELEASE - THALLION AND LFB TERMINATE SHIGAMABS COLLABORATION Montréal, February 20, Thallion Pharmaceuticals Inc. (TSX-V: TLN) ("Thallion") and LFB Biotechnologies ("LFB") today announced that they have